Literature DB >> 20359971

Mimic hypoxia improves angiogenesis in ischaemic random flaps.

Rui Weng1, Qingfeng Li, Hua Li, Mei Yang, Lingling Sheng.   

Abstract

BACKGROUND: Hypoxia is the original signal to promote angiogenesis in ischaemic tissues. However, hypoxia-induced angiogenesis usually cannot compensate for the ischaemic injury in surgery, resulting in tissue necrosis. Mimic hypoxia may be an option to improve angiogenesis for the purpose of preventing or reducing necrosis. In this study, the authors explored the feasibility of applying hypoxic mimic--deferoxamine (DFO) to the treatment of ischaemic random skin flaps.
METHODS: Ischaemic random skin flap models were developed in 18 nude mice using a cutaneous marking technique. The mice were divided into a DFO-treated group and a control group. Vascular endothelial growth factor (VEGF) protein level, vessel density and flap survival rate were evaluated on the seventh postoperative day. In vitro, both VEGF mRNA expression and protein level were investigated in endothelial cells and fibroblasts under DFO, hypoxia and normoxia conditions. The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to study the impact of DFO-induced VEGF up-regulation on endothelial cell viability after severe hypoxia injury.
RESULTS: The flap survival rate, vessel density and VEGF level in the DFO group are significantly higher than in the control group. In vitro, DFO-induced increase in VEGF mRNA expression translated into 2.3- and 5.8-fold increases in VEGF protein secretion in DFO-conditioned media of endothelial cells and fibroblasts, respectively. The MTT assay showed that the cell viability both in the DFO group and in the VEGF group was significantly higher than in the control group.
CONCLUSION: VEGF praracrine and autocrine secretion in fibroblasts and in endothelial cells play an important role in DFO-induced angiogenesis, which improves ischaemic flap survival. DFO-induced VEGF autocrine secretion also protects endothelial cells from severe hypoxia injury. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359971     DOI: 10.1016/j.bjps.2010.02.001

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  6 in total

1.  The hypoxic preconditioning agent deferoxamine induces poly(ADP-ribose) polymerase-1-dependent inhibition of the mitochondrial respiratory chain.

Authors:  Ana Cañuelo; Rubén Martínez-Romero; Esther Martínez-Lara; José A Sánchez-Alcázar; Eva Siles
Journal:  Mol Cell Biochem       Date:  2011-12-07       Impact factor: 3.396

2.  Tanshinone IIA pretreatment protects free flaps against hypoxic injury by upregulating stem cell-related biomarkers in epithelial skin cells.

Authors:  Zihan Xu; Lijun Wu; Yaowen Sun; Yadong Guo; Gaoping Qin; Shengzhi Mu; Ronghui Fan; Benfeng Wang; Wenjie Gao; Zhenxin Zhang
Journal:  BMC Complement Altern Med       Date:  2014-09-04       Impact factor: 3.659

3.  Reusing of the failing free flap "nutrient flap" as salvage procedure.

Authors:  Koji Takahashi; Ching-Hua Hsieh; Seng-Feng Jeng
Journal:  Plast Reconstr Surg Glob Open       Date:  2014-02-07

4.  Local injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1α and VEGF expression.

Authors:  Chen Wang; Yuanyuan Cai; Yun Zhang; Zhuyou Xiong; Guangzao Li; Lei Cui
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

5.  Tanshinone IIA pretreatment renders free flaps against hypoxic injury through activating Wnt signaling and upregulating stem cell-related biomarkers.

Authors:  Zihan Xu; Zhenxin Zhang; Lijun Wu; Yaowen Sun; Yadong Guo; Gaoping Qin; Shengzhi Mu; Ronghui Fan; Benfeng Wang; Wenjie Gao
Journal:  Int J Mol Sci       Date:  2014-10-09       Impact factor: 5.923

6.  Novel skin chamber for rat ischemic flap studies in regenerative wound repair.

Authors:  Yuan-Yu Hsueh; Duo-Hsiang Wang; Tzu-Chieh Huang; Ya-Ju Chang; Wei-Chi Shao; Tai-Lan Tuan; Michael W Hughes; Chia-Ching Wu
Journal:  Stem Cell Res Ther       Date:  2016-05-17       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.